These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32804464)

  • 1. Successful Treatment of Pandrug-resistant Klebsiella pneumoniae Infection With Ceftazidime-avibactam in a Preterm Infant: A Case Report.
    Coskun Y; Atici S
    Pediatr Infect Dis J; 2020 Sep; 39(9):854-856. PubMed ID: 32804464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Ceftazidime-avibactam for the Treatment of Extensively drug-resistant or Pan drug-resistant Klebsiella pneumoniae in Neonates and Children <5 Years of Age.
    Iosifidis E; Chorafa E; Agakidou E; Kontou A; Violaki A; Volakli E; Christou EI; Zarras C; Drossou-Agakidou V; Sdougka M; Roilides E
    Pediatr Infect Dis J; 2019 Aug; 38(8):812-815. PubMed ID: 31135647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment.
    Galani I; Karaiskos I; Angelidis E; Papoutsaki V; Galani L; Souli M; Antoniadou A; Giamarellou H
    Eur J Clin Microbiol Infect Dis; 2021 Jan; 40(1):219-224. PubMed ID: 32729059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of ceftazidime-avibactam resistance through in-vivo bla
    Lai YC; Lin LW; Lee YL
    Int J Antimicrob Agents; 2024 Aug; 64(2):107213. PubMed ID: 38795929
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
    [No Abstract]   [Full Text] [Related]  

  • 7. Lumbar arthrodesis infection by multi-resistant Klebsiella pneumoniae, successfully treated with implant retention and ceftazidime/avibactam.
    Rico-Nieto A; Moreno-Ramos F; Fernández-Baillo N
    Rev Esp Cir Ortop Traumatol (Engl Ed); 2018; 62(6):471-473. PubMed ID: 29636227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate.
    Both A; Büttner H; Huang J; Perbandt M; Belmar Campos C; Christner M; Maurer FP; Kluge S; König C; Aepfelbacher M; Wichmann D; Rohde H
    J Antimicrob Chemother; 2017 Sep; 72(9):2483-2488. PubMed ID: 28637339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing Characteristics and
    Mavroidi A; Katsiari M; Likousi S; Palla E; Roussou Z; Nikolaou C; Mathas C; Merkouri E; Platsouka ED
    Microb Drug Resist; 2020 Jan; 26(1):28-37. PubMed ID: 31386596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cure of recurring Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae septic shock episodes due to complicated soft tissue infection using a ceftazidime and avibactam-based regimen: a case report.
    Parruti G; Frattari A; Polilli E; Savini V; Sciacca A; Consorte A; Cibelli DC; Agostinone A; Di Masi F; Pieri A; Cacciatore P; Di Iorio G; Fazii P; Spina T
    J Med Case Rep; 2019 Jan; 13(1):20. PubMed ID: 30665450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.
    Shields RK; Nguyen MH; Chen L; Press EG; Potoski BA; Marini RV; Doi Y; Kreiswirth BN; Clancy CJ
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel CMY-186 variant conferring cross-resistance to cefiderocol and ceftazidime/avibactam in Klebsiella pneumoniae from a critically ill patient during cefiderocol and ceftazidime/avibactam treatment.
    Amadesi S; Gatti M; Rinaldi M; Pea F; Viale P; Gaibani P
    Int J Antimicrob Agents; 2024 Apr; 63(4):107107. PubMed ID: 38325723
    [No Abstract]   [Full Text] [Related]  

  • 13. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.
    Göttig S; Frank D; Mungo E; Nolte A; Hogardt M; Besier S; Wichelhaus TA
    J Antimicrob Chemother; 2019 Nov; 74(11):3211-3216. PubMed ID: 31365094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.
    Gaibani P; Campoli C; Lewis RE; Volpe SL; Scaltriti E; Giannella M; Pongolini S; Berlingeri A; Cristini F; Bartoletti M; Tedeschi S; Ambretti S
    J Antimicrob Chemother; 2018 Jun; 73(6):1525-1529. PubMed ID: 29566151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
    Papadimitriou-Olivgeris M; Bartzavali C; Lambropoulou A; Solomou A; Tsiata E; Anastassiou ED; Fligou F; Marangos M; Spiliopoulou I; Christofidou M
    J Antimicrob Chemother; 2019 Jul; 74(7):2051-2054. PubMed ID: 31002313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful ceftazidime-avibactam treatment of MDR-KPC-positive Klebsiella pneumoniae infection in a patient with traumatic brain injury: A case report.
    Gugliandolo A; Caio C; Mezzatesta ML; Rifici C; Bramanti P; Stefani S; Mazzon E
    Medicine (Baltimore); 2017 Aug; 96(31):e7664. PubMed ID: 28767588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftazidime-avibactam in urinary tract infections due to carbapenemase-producing Klebsiella in kidney transplantation.
    Caravaca-Fontán F; Jiménez-Álvaro S; Marcén-Letosa R; Fernández-Rodríguez A; Rodríguez-Navarro CQ
    Nefrologia; 2015; 35(4):412-3. PubMed ID: 26306955
    [No Abstract]   [Full Text] [Related]  

  • 18.
    Monogue ML; Abbo LM; Rosa R; Camargo JF; Martinez O; Bonomo RA; Nicolau DP
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
    Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug-resistant
    Galani I; Karaiskos I; Giamarellou H
    Expert Rev Anti Infect Ther; 2021 Nov; 19(11):1457-1468. PubMed ID: 33945387
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.